A detailed history of Hrt Financial LP transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Hrt Financial LP holds 178,413 shares of LRMR stock, worth $681,537. This represents 0.01% of its overall portfolio holdings.

Number of Shares
178,413
Holding current value
$681,537
% of portfolio
0.01%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$6.3 - $10.68 $1.12 Million - $1.91 Million
178,413 New
178,413 $1.17 Million
Q1 2023

May 12, 2023

BUY
$4.0 - $6.68 $312,628 - $522,088
78,157 New
78,157 $354,000
Q4 2021

Feb 14, 2022

SELL
$8.86 - $13.47 $187,601 - $285,213
-21,174 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$9.61 - $15.11 $203,482 - $319,939
21,174 New
21,174 $244,000
Q2 2021

Aug 16, 2021

SELL
$8.0 - $15.2 $226,720 - $430,768
-28,340 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$14.61 - $22.19 $414,047 - $628,864
28,340 New
28,340 $414,000

Others Institutions Holding LRMR

About Larimar Therapeutics, Inc.


  • Ticker LRMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,269,200
  • Market Cap $165M
  • Description
  • Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...
More about LRMR
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.